C9015 Haegarda Injection Reimbursement & Policy

HCPCS Level II code C9015 represents the injectable biologic product C1 esterase inhibitor (human), Haegarda, in 10-unit increments. This code identifies the drug product itself for billing in outpatient and ambulatory settings and is important for accurate tracking of high-cost specialty pharmaceuticals used to treat hereditary angioedema and related C1 inhibitor deficiencies. Nationally, consistent coding supports appropriate reimbursement, utilization management, and pharmacovigilance for biologic therapies.

Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for C9015, typical sites of service, and the role of this HCPCS Level II code in billing workflows. The publication also summarizes payer coverage patterns and benchmarking where available, notes of relevant policy updates affecting specialty drug coding and billing, and guidance on documentation elements commonly associated with injectable biologic administration. Practical takeaways include recognition of C9015 as a drug-specific HCPCS Level II code, implications for outpatient infusion and office-based drug administration, and points to consider for claims processing and utilization oversight.

Data not available in the input for specific modifiers, taxonomies, ICD-10 pairings, and related service lines.

Billing Code Overview

HCPCS Level II code C9015 denotes injection, C1 esterase inhibitor (human), Haegarda, 10 units. This code represents a biologic therapeutic product supplied as an injectable formulation used for replacement therapy of C1 esterase inhibitor deficiency.

Service type: Injectable biologic administration (drug product)
Typical site of service: Outpatient infusion clinic, physician office, or ambulatory care setting

Data not available in the input.

Clinical Context

A typical patient is an adult with hereditary angioedema (HAE) presenting for routine prophylactic self- or clinic-administered replacement therapy with a C1 esterase inhibitor (human) product, Haegarda, dosed in units. The service involves preparation and subcutaneous injection of C9015 (Haegarda) in a clinic, infusion center, or patient home setting under supervision. The clinical workflow includes verification of the patient identity and diagnosis, review of current HAE attack frequency and prior response to C1 inhibitor therapy, medication reconciliation, reconstitution/withdrawal of the prescribed dose, injection site selection and aseptic technique, patient observation for immediate adverse reactions (typically 15–30 minutes), and documentation of lot number, units administered, and any patient education provided. Typical sites of service are outpatient clinic, ambulatory infusion center, or home health/self-administration with clinician oversight. Common payors for coverage considerations include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.

Coding Specifications

Modifier	Description	When to Use
`51`	Multiple Procedures	When multiple distinct procedures or services are billed on the same day and the payer requires identification of multiple procedure billing; used if this injection is billed alongside other procedures that may be reduced.

Taxonomy Code	Specialty	Notes
207P00000X	Allergy & Immunology	Specialists who diagnose and manage hereditary angioedema and prescribe C1 esterase inhibitor therapy.
207L00000X	Hematology	Hematologists who may manage complement disorders and coordinate prophylactic biologic therapy.
207RI0002X	Allergy/Immunology Nurse Practitioner	Advanced practice providers who administer or supervise subcutaneous biologic injections.
363A00000X	Ambulatory Infusion Center	Facility-based taxonomy representing providers who administer parenteral biologic therapies.
2084P0800X	Internal Medicine	Primary care physicians who may prescribe and monitor long-term prophylactic therapy for HAE.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D84.1`	Hereditary deficiency of C1-esterase inhibitor	Primary indication for therapeutic and prophylactic administration of C1 esterase inhibitor (Haegarda).
`T78.2XXA`	Anaphylactic shock, unspecified, initial encounter	Relevant as a potential acute adverse reaction to biologic administration that may require monitoring and treatment.
`R60.0`	Localized edema	Symptom that can be part of angioedema presentations treated with C1 inhibitor replacement.
`R60.9`	Edema, unspecified	General edema code that may appear in differential documentation when angioedema is not specifically coded.
`Z79.899`	Other long term (current) drug therapy	Used to document chronic ongoing prophylactic therapy with biologic agents such as Haegarda.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	Used to report the administration service when `C9015` (Haegarda) is given subcutaneously in clinic settings.
`96401`	Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic (single or initial substance/drug)	Occasionally used in payer-specific cases for biologic injections if payer maps biologics to administration codes in this series (verify payer guidance).
`99024`	Postoperative follow-up visit, included in global service; typically used when related follow-up is not billed separately	Rarely applicable; included for completeness when brief post-administration follow-up is bundled with another global procedure.
`99070`	Supplies and materials (except spectacles), used for the provision of non-covered items such as syringes, needles, and other supplies associated with drug administration	Used to report non-covered disposable supplies provided during injection when payers require separate supply charge reporting.
`G0498`	Hospital outpatient clinic visit for assessment and management of a patient	Used for facility billing when Haegarda administration occurs in an outpatient hospital clinic and facility-level visit reporting is required.

OpenPayer

Summary & Overview

HCPCS C9015: C1 Esterase Inhibitor (Haegarda), Injection, 10 Units